FDA Announced diazepam shortage

July 19, 2022

The FDA announced that there is an ongoing shortage of both brand and generic forms of diazepam rectal gel. This medication is used for rescue therapy in people with epilepsy, including children. The Epilepsy Foundation strongly encourages you to speak with your healthcare provider about your/your child’s options for rescue therapy, since new FDA-approved rescue therapy products have entered the market.

Learn more about rescue therapies at https://www.epilepsy.com/treatment/seizure-rescue-therapies

Related Posts

Recall – Vigabatrin for Oral Solution USP

Recall – Vigabatrin for Oral Solution USP

TOPIC: Vigabatrin for Oral Solution USP, 500 mg by InvaGen Pharmaceuticals: Recall - Due to Leaking Sachets AUDIENCE: Patient, Health Professional, Pharmacy, Pediatric, Neurology ISSUE: InvaGen Pharmaceuticals is recalling one lot, NB301030, of Vigabatrin for Oral...

FDA Warns of Rare but Serious Drug Reaction

FDA Warns of Rare but Serious Drug Reaction

The Dup15q Alliance is aware of the recent release by the FDA regarding Keppra, Keppra XR, Elepsia XR, Spritam (levetiracetam) and Onfi, Sympazan (clobazam) warning about the risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). This adverse event is...

Medication Recall Alert Sabril® (Vigabatrin)

Medication Recall Alert Sabril® (Vigabatrin)

Our friends at the Epielpsy Foundation have shared the Following Medication Recall The company that makes Sabril® (vigabatrin) for oral solution, a prescription medication to manage seizures in children and adults, has announced a recall of this medication because of...